Showing 4481-4490 of 5646 results for "".
- Heidelberg Engineering and RetInSight to Offer AI-Based OCT Fluid Quantification Solutionhttps://modernod.com/news/heidelberg-engineering-and-retinsight-to-offer-ai-based-oct-fluid-quantification-solution/2479136/Heidelberg Engineering and RetInSight announced they intend to interface the RetInSight AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using cloud exchange and application marketplace technologies. RetInSight utilizes a novel, proprietary algorithm, t
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479128/Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases, announced it will participate and have poster
- Market Scope: Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market Through 2026https://modernod.com/news/backlog-of-6-million-cataract-surgeries-will-help-drive-iol-market-through-2026/2479127/Pandemic-impacted 2020 led to a backlog of more than 6 million cataract surgeries globally, as procedures declined 25 percent to 22 million, the lowest number since 2010, mainly due to COVID-related shutdowns in elective surgeries, according to a Market Scope report. The amount of time it
- Hoya Vision Care Releases Results of 3-Year MiYOSMART Spectacle Lens Follow-up Studyhttps://modernod.com/news/hoya-vision-care-releases-results-of-3-year-miyosmart-spectacle-lens-follow-up-study/2479124/Hoya Vision Care shared the results of a 3-year follow-up clinical study on its MiYOSMART spectacle lens with patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology after releasing the information at the recent European Academy of Optometry and Optics (EAOO) ’21 conference. T
- SIFI Initiates Patient Enrollment in Phase 2 Trial Evaluating Pro-Ocular in Dry Eye Diseasehttps://modernod.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/SIFI announced the enrollment of the first patients in the ProGIFT trial, which aims to evaluate the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with dry eye disease (DED). P<
- Oertli Launches New Silicone Application Adapterhttps://modernod.com/news/oertli-launches-new-silicone-application-adapter/2479114/Oertli announced it has released a new silicone application that is designed to allow for more user-friendly and efficient surgical preparation. The Oertli silicone application sets deliver fast injection and extraction of silicone oil, according to a company news release. The universal vi
- Orasis Pharmaceuticals Appoints Industry Veteran Paul Smith as President and Chief Operating Officerhttps://modernod.com/news/orasis-pharmaceuticals-appoints-industry-veteran-paul-smith-as-president-and-chief-operating-officer/2479112/Orasis Pharmaceuticals announced the appointment of Paul Smith as president and chief operating officer (COO). Mr. Smith brings over two decades of leadership in eye care. “I am excited to join Orasis Pharmaceuticals at such a pivotal time in the company’s h
- Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollmenthttps://modernod.com/news/nicoxs-ncx-4251-mississippi-phase-2b-blepharitis-trial-reaches-50-enrollment/2479109/Nicox SA announced that 102 patients in the NCX 4251 Mississippi phase 2b blepharitis clinical trial have now been randomized out of a target of 200, with topline results currently on track to be announced during Q4 2021. “Achievement of 50% enrollment in this phase 2b trial of NCX 4251 in
- US Patents for Nicox’s Vyzulta (Latanoprostene Bunod) Eligible for Patent Term Extensionhttps://modernod.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potential